(Q53122333)

11 May 2018

title

Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors. (English)

1 reference

11 May 2018

1 reference

1 reference

1

Ursula A Matulonis

1 reference

11 May 2018

author name string

Karen J Krag

2

1 reference

11 May 2018

Carolyn N Krasner

3

1 reference

11 May 2018

Tina Atkinson

4

1 reference

11 May 2018

Neil S Horowitz

5

1 reference

11 May 2018

Hang Lee

6

1 reference

11 May 2018

Richard T Penson

7

1 reference

11 May 2018

language of work or name

English

0 references

publication date

5 December 2008

1 reference

11 May 2018

published in

Gynecologic Oncology

1 reference

11 May 2018

volume

112

1 reference

11 May 2018

issue

2

1 reference

11 May 2018

page(s)

394-399

1 reference

11 May 2018

Management of ovarian cancer in patients older than 80 years of Age.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Surgical care of elderly women with ovarian cancer: a population-based perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Underrepresentation of patients 65 years of age or older in cancer-treatment trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Determinants of survival in older cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Gynecologic oncologic surgery in the elderly: A retrospective analysis of 213 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Response and outcomes in elderly patients with stages IIIC–IV ovarian cancer receiving platinum–taxane chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Is there an optimal comorbidity index for prostate cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.10.015

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2008.10.015

1 reference

11 May 2018

1 reference

11 May 2018